Literature DB >> 29365411

[Report of Cancer Incidence and Mortality in China, 2014].

W Q Chen1, H Li1, K X Sun1, R S Zheng1, S W Zhang1, H M Zeng1, X N Zou1, X Y Gu2, J He3.   

Abstract

Objective: The registration data of local cancer registries in 2014 were collected by National Central Cancer Registry (NCCR)in 2017 to estimate the cancer incidence and mortality in China.
Methods: The data submitted from 449 registries were checked and evaluated, and the data of 339 registries out of them were qualified and selected for the final analysis. Cancer incidence and mortality were stratified by area, gender, age group and cancer type, and combined with the population data of 2014 to estimate cancer incidence and mortality in China. The age composition of standard population of Chinese census in 2000 and Segi's population were used for age-standardized incidence and mortality in China and worldwide, respectively.
Results: Total covered population of 339 cancer registries (129 in urban and 210 in rural) in 2014 were 288 243 347 (144 061 915 in urban and 144 181 432 in rural areas). The mortality verified cases (MV%) were 68.01%. Among them, 2.19% cases were identified through death certifications only (DCO%), and the mortality to incidence ratio was 0.61. There were about 3, 804, 000 new cases diagnosed as malignant cancer and 2, 296, 000 cases dead in 2014 in the whole country. The incidence rate was 278.07/100, 000 (males 301.67/100, 000, females 253.29/100, 000) in China, age-standardized incidence rates by Chinese standard population (ASIRC) and by world standard population were 190.63/100, 000 and 186.53/100, 000, respectively, and the cumulative incidence rate (0-74 age years old) was 21.58%. The cancer incidence and ASIRC in urban areas were 302.13/100, 000 and 196.58/100, 000, respectively, whereas in rural areas, those were 248.94/100, 000 and 182.64/100, 000, respectively. The cancer mortality in China was 167.89/100, 000 (207.24/100, 000 in males and 126.54/100, 000 in females), age-standardized mortality rates by Chinese standard population (ASMRC) and by world standard population were 106.98/100, 000 and 106.09/100, 000, respectively. And the cumulative incidence rate (0-74 age years old) was 12.00%. The cancer mortality and ASMRC in urban areas were 174.34/100, 000 and 103.49/100, 000, respectively, whereas in rural areas, those were 160.07/100, 000 and 111.57/100, 000, respectively. Lung cancer, gastric cancer, colorectal cancer, liver cancer, female breast cancer, esophageal cancer, thyroid cancer, cervical cancer, encephala and pancreas cancer, were the most common cancers in China, accounting for about 77.00% of the new cancer cases. Lung cancer, liver cancer, gastric cancer, esophageal cancer, colorectal cancer, pancreatic cancer, breast cancer, encephala, leukemia and lymphoma were the leading causes of death and accounted for about 83.36% of cancer deaths. Conclusions: The progression of cancer registry in China develops rapidly in these years, with the coverage of registrations is expanded and the data quality was improved steadily year by year. As the basis of cancer prevention and control program, cancer registry plays an important role in making the medium and long term of anti-cancer strategies in China. As China is still facing the serious cancer burden and the cancer patterns varies differently according to the locations and genders, effective measures and strategies of cancer prevention and control should be implemented based on the practical situation.

Entities:  

Keywords:  Cancer registry; China; Incidence; Malignant tumor; Mortality

Mesh:

Year:  2018        PMID: 29365411     DOI: 10.3760/cma.j.issn.0253-3766.2018.01.002

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  64 in total

1.  Knockdown of eukaryotic translation initiation factor 3 subunit B inhibits cell proliferation and migration and promotes apoptosis by downregulating WNT signaling pathway in acute myeloid leukemia.

Authors:  Yonghuai Feng; Liusong Wu
Journal:  Int J Clin Exp Pathol       Date:  2020-01-01

2.  Chinese Cancer Patients' Attitudes Toward Psychotherapy and Their Willingness to Participate in Clinical Trials of Psychotherapy.

Authors:  Zhi Zeng; Yaotiao Deng; Jie Liu; Keyi Yang; Hu Peng; Yu Jiang
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 2.339

3.  Long non-coding RNA LINC02446 suppresses the proliferation and metastasis of bladder cancer cells by binding with EIF3G and regulating the mTOR signalling pathway.

Authors:  Xiaotong Zhang; Jiarun Zhang; Wei Zhao; Xiao Dong; Peng Xin; Xi Liu; Xuejie Li; Zhifei Jing; Zhe Zhang; Chuize Kong; Xiuyue Yu
Journal:  Cancer Gene Ther       Date:  2021-02-02       Impact factor: 5.987

4.  Construction of a prognostic model for non-small-cell lung cancer based on ferroptosis-related genes.

Authors:  Ke Han; Jukun Wang; Kun Qian; Teng Zhao; Xingsheng Liu; Yi Zhang
Journal:  Biosci Rep       Date:  2021-05-28       Impact factor: 3.840

5.  Silibinin induces G1 arrest, apoptosis and JNK/SAPK upregulation in SW1990 human pancreatic cancer cells.

Authors:  Xiaokai Zhang; Jiming Liu; Peng Zhang; Liting Dai; Zhihui Wu; Li Wang; Mingrong Cao; Jianwei Jiang
Journal:  Oncol Lett       Date:  2018-04-19       Impact factor: 2.967

6.  Bcl-2/Bcl-xl inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma.

Authors:  Hanjie Yi; Miao-Zhen Qiu; Luping Yuan; Qiuyun Luo; Wentao Pan; Suna Zhou; Lin Zhang; Xianglei Yan; Da-Jun Yang
Journal:  Cancer Med       Date:  2020-04-28       Impact factor: 4.452

7.  Inhibition of Serine Metabolism Promotes Resistance to Cisplatin in Gastric Cancer.

Authors:  Xiaoya Zhao; Jianfei Fu; Wanfen Tang; Liangliang Yu; Wenxia Xu
Journal:  Onco Targets Ther       Date:  2020-05-29       Impact factor: 4.147

8.  The prognostic value of USP14 and PSMD14 expression in non-small cell lung cancer.

Authors:  Jian Lei; Xiaoliu Liu; Wei Liu; Yun Zhang; Zhihong Liu
Journal:  Ann Transl Med       Date:  2021-06

9.  Sarcopenia in Patients With Normal Body Mass Index Is an Independent Predictor for Postoperative Complication and Long-Term Survival in Gastric Cancer.

Authors:  Xiangwei Sun; Jianfeng Xu; Xiaodong Chen; Weiteng Zhang; Wenjing Chen; Ce Zhu; Jing Sun; Xinxin Yang; Xiang Wang; Yingying Hu; Yiqi Cai; Xian Shen
Journal:  Clin Transl Sci       Date:  2021-05-01       Impact factor: 4.689

10.  Mediastinoscopy-assisted esophagectomy for T2 middle and lower thoracic esophageal squamous cell carcinoma patients.

Authors:  Jun Wang; Ning Wei; Yimin Lu; Xiaoying Zhang; Nanqing Jiang
Journal:  World J Surg Oncol       Date:  2018-03-16       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.